Search research articles
Contact Us
Filters
Showing results (211-220 of 278) with videos related to
Page
of 28
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2026
Mechanisms of Clinical Resistance to Selective FGFR2 Inhibition by Lirafugratinib
H Ellis, E R Balasooriya, A Varkaris, et al.
Cancer Discovery
|
March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
Ryan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
The Oncologist
|
April 5, 2021
Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss
Till Dominik Best, Eric J Roeland, Nora K Horick, et al.
The Oncologist
|
May 2, 2019
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy
Aparna R Parikh, Yuting He, Ted S Hong, et al.
Science Translational Medicine
|
August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma
Ryan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
The Lancet. Respiratory Medicine
|
June 9, 2026
Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial
Kate Leslie, Jai N Darvall, Matthew T V Chan, et al.
Cancer Medicine
|
May 18, 2018
Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis
Sophia C Kamran, Jeffrey W Clark, Hui Zheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2015
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B Corcoran, Chloe E Atreya, Gerald S Falchook, et al.
Cancer Discovery
|
December 3, 2017
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
John H Strickler, Jonathan M Loree, Leanne G Ahronian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2025
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer
Rachel O Abelman, Bogang Wu, Haley Barnes, et al.
Page
of 28
Search research articles
Search
Showing results (211-220 of 278) with videos related to
Sort By:
Page
of 28
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2026
Mechanisms of Clinical Resistance to Selective FGFR2 Inhibition by Lirafugratinib
H Ellis, E R Balasooriya, A Varkaris, et al.
Cancer Discovery
|
March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
Ryan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
The Oncologist
|
April 5, 2021
Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss
Till Dominik Best, Eric J Roeland, Nora K Horick, et al.
The Oncologist
|
May 2, 2019
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy
Aparna R Parikh, Yuting He, Ted S Hong, et al.
Science Translational Medicine
|
August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma
Ryan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
The Lancet. Respiratory Medicine
|
June 9, 2026
Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial
Kate Leslie, Jai N Darvall, Matthew T V Chan, et al.
Cancer Medicine
|
May 18, 2018
Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis
Sophia C Kamran, Jeffrey W Clark, Hui Zheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2015
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B Corcoran, Chloe E Atreya, Gerald S Falchook, et al.
Cancer Discovery
|
December 3, 2017
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
John H Strickler, Jonathan M Loree, Leanne G Ahronian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2025
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer
Rachel O Abelman, Bogang Wu, Haley Barnes, et al.
Page
of 28